… of cisplatin in first-line combination regimens for NSCLC, the issues … biological therapy.
The non-selective application of EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib …

… NSCLC, with a brief review of the future potential of biologic … as the phase II BLOT regimen),39
as well as daily celecoxib, … Results of a phase III trial of erlotinib (OSI-774) combined with …

… The EGFR inhibitors gefitinib and erlotinib are currently … inhibit multiple pathways that are
biologically relevant in NSCLCs (… In this regard, a trial combining ganetespib and rapamycin is …

… as E-cadherin leads to resistance to erlotinib (E), and PGE2 … phase I study of E and celecoxib
(C) established the optimal … targeted population who will benefit from combination COX-2 …

… The other is a phase I study evaluating rosuvastatin with erlotinib in patient … phase II trial
evaluating celecoxib 400 mg oral bid in combination with gefitinib 250 mg oral daily in advanced-…

… of docetaxel and the specific COX-2 inhibitor celecoxib. … -agent and combination therapy
in nonsmall cell lung cancer. … erlotinib in patients with recurrent non-small cell lung cancer (…

… the combination of COX-2 inhibition (celecoxib) and EGFR inhibition (erlotinib) in a phase I
trial in advanced non-small cell lung … biologic dose (OBD) of the combination of celecoxib and …

… An increased understanding of the biology of lung cancer has … , gefitinib and erlotinib were
combined with chemotherapy early in … administered with the COX-2 inhibitor celecoxib (22). A …

… phase 3 trials of erlotinib (Tarceva), which demonstrated negative results when combined
with polychemotherapy in untreated, advanced … The cyclooxygenase-2 inhibitors celecoxib …

… vanced Lung Cancer 1 and 2 (IDEAL 1 and 2), have … Thus, the combination of gefitinib
or erlotinib with … A pilot study has shown the feasibility of celecoxib with docetaxel …